Literature DB >> 35092559

CRISPR Technology in Cancer Diagnosis and Treatment: Opportunities and Challenges.

Behrouz Shademan1, Sepideh Masjedi2, Vahidreza Karamad1, Alireza Isazadeh3, Fatma Sogutlu1, Mohammad Hosein Saeedi Rad4, Alireza Nourazarian5.   

Abstract

A novel gene editing tool, the Cas system, associated with the CRISPR system, is emerging as a potential method for genome modification. This simple method, based on the adaptive immune defense system of prokaryotes, has been developed and used in human cancer research. These technologies have tremendous therapeutic potential, especially in gene therapy, where a patient-specific mutation is genetically corrected to cure diseases that cannot be cured with conventional treatments. However, translating CRISPR/Cas9 into the clinic will be challenging, as we still need to improve the efficiency, specificity, and application of the technology. In this review, we will explain how CRISPR-Cas9 technology can treat cancer at the molecular level, focusing on ordination and the epigenome. We will also focus on the promise and shortcomings of this system to ensure its application in the treatment and prevention of cancer.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CRISPR; Cancer treatment; Gene editing; Solid tumors

Mesh:

Year:  2022        PMID: 35092559     DOI: 10.1007/s10528-022-10193-9

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   2.220


  106 in total

1.  CRISPR provides acquired resistance against viruses in prokaryotes.

Authors:  Rodolphe Barrangou; Christophe Fremaux; Hélène Deveau; Melissa Richards; Patrick Boyaval; Sylvain Moineau; Dennis A Romero; Philippe Horvath
Journal:  Science       Date:  2007-03-23       Impact factor: 47.728

2.  CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells.

Authors:  Xiangning Bu; Jiro Kato; Julie A Hong; Maria J Merino; David S Schrump; Frances E Lund; Joel Moss
Journal:  Carcinogenesis       Date:  2018-02-09       Impact factor: 4.944

Review 3.  Viral gene therapy for breast cancer: progress and challenges.

Authors:  Antonela S Asad; Mariela A Moreno Ayala; M Florencia Gottardo; Camila Zuccato; Alejandro Javier Nicola Candia; Flavia A Zanetti; Adriana Seilicovich; Marianela Candolfi
Journal:  Expert Opin Biol Ther       Date:  2017-06-12       Impact factor: 4.388

4.  Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs).

Authors:  Adriana S Beltran; Pilar Blancafort
Journal:  Epigenetics       Date:  2011-02-01       Impact factor: 4.528

5.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

6.  Multiplexed and tunable transcriptional activation by promoter insertion using nuclease-assisted vector integration.

Authors:  Alexander Brown; Jackson Winter; Michael Gapinske; Nathan Tague; Wendy S Woods; Pablo Perez-Pinera
Journal:  Nucleic Acids Res       Date:  2019-07-09       Impact factor: 16.971

Review 7.  Cancer is a preventable disease that requires major lifestyle changes.

Authors:  Preetha Anand; Ajaikumar B Kunnumakkara; Ajaikumar B Kunnumakara; Chitra Sundaram; Kuzhuvelil B Harikumar; Sheeja T Tharakan; Oiki S Lai; Bokyung Sung; Bharat B Aggarwal
Journal:  Pharm Res       Date:  2008-07-15       Impact factor: 4.200

8.  Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.

Authors:  Mouadh Benamar; Fadila Guessous; Kangping Du; Patrick Corbett; Joseph Obeid; Daniel Gioeli; Craig L Slingluff; Tarek Abbas
Journal:  EBioMedicine       Date:  2016-06-16       Impact factor: 8.143

9.  In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa.

Authors:  Benjamin Bakondi; Wenjian Lv; Bin Lu; Melissa K Jones; Yuchun Tsai; Kevin J Kim; Rachelle Levy; Aslam Abbasi Akhtar; Joshua J Breunig; Clive N Svendsen; Shaomei Wang
Journal:  Mol Ther       Date:  2015-12-15       Impact factor: 11.454

View more
  2 in total

Review 1.  Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis.

Authors:  Dave N T Aryee; Valerie Fock; Utkarsh Kapoor; Branka Radic-Sarikas; Heinrich Kovar
Journal:  Cells       Date:  2022-04-08       Impact factor: 7.666

Review 2.  Advances in CRISPR/Cas9.

Authors:  Youmin Zhu
Journal:  Biomed Res Int       Date:  2022-09-23       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.